Capital Pharma s.r.o.Active
Key figures
Key figures
2025Balance sheet structure
Summary of annual reports2020–2025
| 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|
| Revenue (net turnover) | 22 000 | 31 500 | 22 500 | 20 000 | 54 000 |
| Profit for the reporting year | -2 760 | -165 | -393 | 540 | 9 294 |
| Retained earnings of previous periods | 19 850 | 17 228 | 17 063 | 16 670 | 17 182 |
| Total assets | 35 514 | 40 651 | 47 947 | 48 135 | 46 188 |
| Total liabilities | 11 712 | 17 014 | 24 703 | 24 351 | 13 111 |
| Total equity | 23 802 | 23 637 | 23 244 | 23 784 | 33 077 |
| Calculated dividends | 0 | 0 | 0 | 0 | 0 |
A dash (—) means the report has not been filed or the line is not reported; 0 is a zero stated in the report.
Summary: Capital Pharma s.r.o.
Overview
Capital Pharma s.r.o. (IČO 36748731) is a limited liability company (s.r.o.). The company was incorporated in 2007 and has existed for 19 years. Registered office according to the register: Bruty. Main activity according to the Statistical Office: činnosti reklamných agentúr (SK NACE 7311).
People
The company has one statutory representative. According to the register, the company has one shareholder. The registered capital is 6 640 €.
Financial results
Revenue for 2025 was 54 000 €, up 170 % on the previous year (20 000 €). From 2020 to 2025, revenue grew by an average of 17,6 % per year. This is the highest revenue in the reported years (2020–2025). Net profit for 2025 was 9 294 € (17,2 % of revenue). The company was profitable in 2 of the 6 reported years. At the end of 2025 the company had total assets of 46 188 € and equity of 33 077 € (equity ratio 71,6 %).
Sources and freshness
Company and people data come from the Register of Legal Entities (Statistical Office SR, CC BY 4.0) and financial statements from the Register of Financial Statements (Ministry of Finance SR); icoprofil.sk updates them daily. Data as of 7. 11. 2026. Changes, averages and ratios are calculated by icoprofil.sk from open data and are not an official assessment.